Sarah Langan

Sarah Langan is an experienced professional with a strong background in synthetic molecule development and analytical processes. Currently serving as Senior Vice President of Synthetic Molecule Development at Eli Lilly and Company since January 2021, Sarah has previously held roles including Associate Vice President of Tides and Analytical Development and Director of CMC PM Diabetes at the same organization. Prior to Eli Lilly, Sarah gained valuable experience as an Engineering Intern at The Dow Chemical Company and Gerber Products Company. Academic credentials include a Master's degree in Biomedical/Medical Engineering from Purdue University and a Bachelor's degree in Chemical Engineering from Rose-Hulman Institute of Technology.